Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced new data supporting the safety, efficacy, and real-world effectiveness of AUSTEDO tablets for treating Huntington's disease (HD) chorea. The data will be presented at the Huntington Study Group® (HSG) Annual Meeting. The results show that 92% of patients achieved optimal dosing by week 12 with the AUSTEDO 4-week patient titration kit. The data also reinforce the efficacy and tolerability of AUSTEDO.